

# Medical Policy: High Frequency Chest Wall Oscillation Devices and Intrapulmonary Percussive Ventilators (Commercial)



POLICY NUMBER	LAST REVIEW DATE	APPROVED BY
MG.MM.DM.09cC2	09/10/2021	MPC (Medical Policy Committee)

### **IMPORTANT NOTE ABOUT THIS MEDICAL POLICY:**

Property of ConnectiCare, Inc. All rights reserved. The treating physician or primary care provider must submit to ConnectiCare, Inc. the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, ConnectiCare will not be able to properly review the request for prior authorization. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. The clinical review criteria expressed below reflects how ConnectiCare determines whether certain services or supplies are medically necessary. ConnectiCare established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). ConnectiCare, Inc. expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. Each benefit plan defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by ConnectiCare, as some plans exclude coverage for services or supplies that ConnectiCare considers medically necessary. If there is a discrepancy between this guideline and a member's benefits plan, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of the State of CT and/or the Federal Government. Coverage may also differ for our Medicare members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including including National Coverage Determinations (NCD), Local Coverage Determinations (LCD) and/or Local Medical Review Policies(LMRP). All coding and web site links are accurate at time of publication.

## Definition

High Frequency Chest Wall Oscillation (HFCWO)	A high frequency chest wall oscillation device (HFCWO) is an airway clearance device consisting of an inflatable vest connected by tubes to a small air-pulse generator.
---	--

## Guideline

Members are eligible for coverage of HFCWO when any of the following conditions/diagnoses met:

1. Acid maltase deficiency
2. Amyotrophic lateral sclerosis
3. Anterior horn cell diseases
4. Bronchiectasis
5. Cystic fibrosis
6. Hereditary muscular dystrophy
7. Multiple sclerosis
8. Myotonic disorders
9. Other myopathies
10. Paralysis of the diaphragm
11. Post-polio

# Medical Policy: High Frequency Chest Wall Oscillation Devices and Intrapulmonary Percussive Ventilators (Commercial)



12. Quadriplegia
13. Any neuromuscular disease disorder with ineffective cough
14. Members with a gastrostomy tube and risk of aspiration if manual chest physical therapy (PT) is indicated on a case by case basis when other methods of daily chest PT have been tried and failed

Well-documented failure of standard treatments to adequately mobilize retained secretions must be made available to the Plan upon request

## Limitation/Exclusion

High frequency chest wall oscillation devices are not covered for any conditions other than those listed above.

Intrapulmonary percussive ventilators (IPV) (e.g., the Impulsator F00012) are considered experimental and investigational for all indications due to insufficient evidence of therapeutic value (including but not limited to bronchiectasis, chronic obstructive pulmonary disease [COPD], cystic fibrosis, neuromuscular conditions associated with retained airway secretions or atelectasis, and post-operative pulmonary complications)

## Applicable Procedure Codes

<b>A7025</b>	High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each
<b>A7026</b>	High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each
<b>E0467</b>	Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions (eff. 01/01/2019)
<b>E0483</b>	High frequency chest wall oscillation air-pulse generator system, (includes hoses and vest), each

## Applicable IDC-10 Diagnosis Codes

<b>A15.0</b>	Tuberculosis of lung
<b>B91</b>	Sequelae of poliomyelitis
<b>D81.810</b>	Biotinidase deficiency
<b>D84.1</b>	Defects in the complement system
<b>E84.0</b>	Cystic fibrosis with pulmonary manifestations
<b>E84.11</b>	Meconium ileus in cystic fibrosis
<b>G12.0</b>	Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
<b>G12.1</b>	Other inherited spinal muscular atrophy
<b>G12.20</b>	Motor neuron disease, unspecified
<b>G12.21</b>	Amyotrophic lateral sclerosis
<b>G12.22</b>	G12.22 Progressive bulbar palsy
<b>G12.23</b>	Primary lateral sclerosis
<b>G12.24</b>	Familial motor neuron disease
<b>G12.25</b>	Progressive spinal muscle atrophy
<b>G12.29</b>	Other motor neuron disease
<b>G12.8</b>	Other spinal muscular atrophies and related syndromes
<b>G12.9</b>	Spinal muscular atrophy, unspecified
<b>G14</b>	Postpolio syndrome

# Medical Policy: High Frequency Chest Wall Oscillation Devices and Intrapulmonary Percussive Ventilators (Commercial)



<b>G35</b>	Multiple sclerosis
<b>G71.00</b>	Muscular dystrophy, unspecified
<b>G71.01</b>	Duchenne or Becker muscular dystrophy
<b>G71.02</b>	Facioscapulohumeral muscular dystrophy
<b>G71.09</b>	Other specified muscular dystrophies
<b>G71.11</b>	Myotonic muscular dystrophy
<b>G71.12</b>	Myotonia congenita
<b>G71.13</b>	Myotonic chondrodystrophy
<b>G71.14</b>	Drug induced myotonia
<b>G71.19</b>	Other specified myotonic disorders
<b>G71.20</b>	Congenital myopathy, unspecified (eff. 10/01/2020)
<b>G71.21</b>	Nemaline myopathy (eff. 10/01/2020)
<del><b>G71.2</b></del>	<del>Congenital myopathies (del. 10/01/2020)</del>
<b>G71.220</b>	X-linked myotubular myopathy (eff. 10/01/2020)
<b>G71.228</b>	Other centronuclear myopathy (eff. 10/01/2020)
<b>G71.29</b>	Other congenital myopathy (eff. 10/01/2020)
<b>G71.3</b>	Mitochondrial myopathy, not elsewhere classified
<b>G71.8</b>	Other primary disorders of muscles
<b>G72.0</b>	Drug-induced myopathy
<b>G72.1</b>	Alcoholic myopathy
<b>G72.2</b>	Myopathy due to other toxic agents
<b>G72.89</b>	Other specified myopathies
<b>G73.7</b>	Myopathy in diseases classified elsewhere
<b>G82.50</b>	Quadriplegia, unspecified
<b>G82.51</b>	Quadriplegia, C1-C4 complete
<b>G82.52</b>	Quadriplegia, C1-C4 incomplete
<b>G82.53</b>	Quadriplegia, C5-C7 complete
<b>G82.54</b>	Quadriplegia, C5-C7 incomplete
<b>J47.0</b>	Bronchiectasis with acute lower respiratory infection
<b>J47.1</b>	Bronchiectasis with (acute) exacerbation
<b>J47.9</b>	Bronchiectasis, uncomplicated
<b>J98.6</b>	Disorders of diaphragm
<b>M33.02</b>	Juvenile dermatomyositis with myopathy
<b>M33.12</b>	Other dermatomyositis with myopathy
<b>M33.22</b>	Polymyositis with myopathy
<b>M33.92</b>	Dermatopolymyositis, unspecified with myopathy
<b>M34.82</b>	Systemic sclerosis with myopathy
<b>M35.03</b>	Sicca syndrome with myopathy
<b>Q33.4</b>	Congenital bronchiectasis

## References

Centers for Medicare and Medicaid Services. National Coverage Determination for Intrapulmonary Percussive Ventilator. July 1997. Available at: [https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=229&ncdver=1&DocID=240.5&ncd\\_id=240.5&ncd\\_version=1&basket=ncd%25253A240%25252E5%25253A1%25253AIntrapulmonary+Percussive+Ventilator+%252528IPV%252529&bc=gAAAAAgAAAA&](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=229&ncdver=1&DocID=240.5&ncd_id=240.5&ncd_version=1&basket=ncd%25253A240%25252E5%25253A1%25253AIntrapulmonary+Percussive+Ventilator+%252528IPV%252529&bc=gAAAAAgAAAA&). Accessed September 23, 2021.

# Medical Policy: High Frequency Chest Wall Oscillation Devices and Intrapulmonary Percussive Ventilators (Commercial)



Deakins K, Chatburn RL. A comparison of intrapulmonary percussive ventilation and conventional chest physiotherapy for the treatment of atelectasis in the pediatric patient. *Respir Care*. 2002; 47(10):1162-1167.

Irwin RS, Baumann MH, Bolser DC, et al.; American College of Chest Physicians (ACCP). Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. *Chest*. 2006; 129(1 Suppl):1S-23S.

Noridian. LCD for High Frequency Chest Wall Oscillation Devices. January 2020. <https://med.noridianmedicare.com/documents/2230703/7218263/High+Frequency+Chest+Wall+Oscillation+Devices/2c8213bc-6773-4dcf-9fa5-80557b80b888>. Accessed September 23, 2021.

Specialty-matched clinical peer review.

Varekojis SM, Douce FH, Flucke RL, et al. A comparison of the therapeutic effectiveness of and preference for postural drainage and percussion, intrapulmonary percussive ventilation, and high-frequency chest wall compression in hospitalized cystic fibrosis patients. *Respir Care*. 2003; 48(1):24-28.

## Revision history

DATE	REVISION
09/13/ 2019	Added the following covered indications to HFDWOD: <ul style="list-style-type: none"><li>• Any neuromuscular disease disorder with ineffective cough</li><li>• Members with a gastrostomy tube and risk of aspiration if manual chest physical therapy (PT) is indicated on a case by case basis when other methods of daily chest PT have been tried and failed</li><li>• Reformatted and reorganized policy, transferred content to new CCI template.</li></ul>
06/10/2016	Communicated noncoverage of IPVs